Microangiopathic hemolytic anemia pathophysiology
|
Microangiopathic hemolytic anemia Microchapters |
|
Differentiating Microangiopathic hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Microangiopathic hemolytic anemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Microangiopathic hemolytic anemia pathophysiology |
|
Microangiopathic hemolytic anemia pathophysiology in the news |
|
Directions to Hospitals Treating Microangiopathic hemolytic anemia |
|
Risk calculators and risk factors for Microangiopathic hemolytic anemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pathophysiology
In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, as well as malignant hypertension, the endothelial layer of small vessels are damaged with resulting fibrin deposition and platelet aggregation. In all causes, the mechanism of MAHA is the formation of a fibrin mesh due to increased activity of the system of coagulation.
Microscopic Pathology
The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.